Date: 2016-04-13
Type of information: Collaboration agreement
Compound:
Company: Sanofi (France) Stevenage Bioscience Catalyst (UK)
Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Immunological diseases - Infectious diseases - Neurodegenerative diseases - Rare diseases
Type agreement: collaboration opening of new premises
Action mechanism:
Disease:
Details: * On April 13th , 2016, Sanofi announced the creation of a partnering office at Stevenage Bioscience Catalyst to engage and collaborate with the network of bioscience companies and academia that form part of the UK’s life sciences ecosystem. This collaboration reflects Sanofi's commitment to open innovation and collaboration that is necessary to accelerate the translation of transformative innovation. The collaboration with Stevenage Bioscience Catalyst is one example of partnering initiatives being led within the UK and Ireland by Sanofi’s External Science & Partnering function. Sanofi works with partners to develop mutually beneficial relationships with the singular focus of advancing high-quality scientific research with the goal of improving the lives of patients in areas of high unmet need. Key areas of research interest to Sanofi include diabetes, cardiovascular disease, rare diseases, vaccines, immunology, oncology, multiple sclerosis, neurodegenerative and infectious diseases.
Stevenage Bioscience Catalyst (SBC) is a UK open innovation biomedical campus that opened in 2012. Backed by a novel partnership between Government, GSK and the Wellcome Trust, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC offers a start-up and grow-on space for companies, plus a commercially focused management team. Co-located with GSK in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge.
Financial terms:
Latest news:
